<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732860</url>
  </required_header>
  <id_info>
    <org_study_id>REFLECT-001</org_study_id>
    <nct_id>NCT02732860</nct_id>
  </id_info>
  <brief_title>Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host</brief_title>
  <acronym>REFLECT</acronym>
  <official_title>Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By obtaining clinical specimens from participants with triple negative breast cancer (TNBC),
      colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor
      types to establish and profile as freshly implanted tumors in mice, the aim of this study is
      to identify agents with predicted activity in the host patient while also potentially
      providing them with personalized cancer treatment options
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Personalized patient-derived xenografts (pPDX) are increasingly used as tools for drug
      development in pre-clinical settings, and have been shown to recapitulate the histology and
      behavior of the cancers from which they are derived. Although, they have been commonly used
      productively as pre-clinical disease models to study disease biology and drug response, they
      have not been used prospectively to inform clinical management. pPDX have been employed to
      inform clinical decision-making in small studies, which have shown high concordance between
      individual pPDX and patient responses to therapy. While encouraging, the role of this
      approach in breast, colorectal, ovarian, and other cancer populations and in the context of
      genomic drug matching strategies remains undefined. This has created an opportunity to
      evaluate the utility of pPDX as clinical predictors to direct the use of chemo- and targeted
      therapies in combination with comprehensive genomic and epigenetic analysis for patients with
      TNBC, CRC, HGSOC and other selected tumor types.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Sensitivity measured by tumor growth inhibition (&gt;80%) or objective tumor response (regression) as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of results reporting</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of pPDX engraftment</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of actionable alterations identified in clinical and pPDX samples</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Genomic alterations identified using the Ion Proton System for Next-Generation Sequencing (NGS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with molecular abnormalities in pPDX as identified via NGS eliciting clinical responses while receiving matched treatments.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Overall accuracy of clinical responses as assessed by RECIST criteria in patient tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between pPDX and organoid drug sensitivities</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Neoplasm</condition>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
    <description>Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).
After the screening procedures confirms patient eligibility:
Molecular Profiling will be performed on clinical sample
pPDX generation for in vivo drug testing
In vitro organoid culture generation (if sufficient fresh tissue available)
Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal Cancer</arm_group_label>
    <description>Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).
After the screening procedures confirms patient eligibility:
Molecular Profiling will be performed on clinical sample
pPDX generation for in vivo drug testing
In vitro organoid culture generation (if sufficient fresh tissue available)
Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Grade Serous Ovarian Cancer</arm_group_label>
    <description>High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).
After the screening procedures confirms patient eligibility:
Molecular Profiling will be performed on clinical sample
pPDX generation for in vivo drug testing
In vitro organoid culture generation (if sufficient fresh tissue available)
Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other tumor types</arm_group_label>
    <description>Other selected tumor types at the discretion of the PI (n= up to 15)
After the screening procedures confirms patient eligibility:
Molecular Profiling will be performed on clinical sample
pPDX generation for in vivo drug testing
In vitro organoid culture generation (if sufficient fresh tissue available)
Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Molecular Profiling &amp; In Vivo drug testing in pPDX and organoid cultures</intervention_name>
    <description>Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.</description>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
    <arm_group_label>Colorectal Cancer</arm_group_label>
    <arm_group_label>High Grade Serous Ovarian Cancer</arm_group_label>
    <arm_group_label>Other tumor types</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, formalin fixed paraffin embedded blocks, fresh tumor tissue, malignant effusion
      or ascites (if no tumor tissue available), archival tissue (if not enrolled in molecular
      profiling studies IMPACT/OCTANE)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with TNBC, CRC, HGSOC, or selected other tumour types, referred to, or being
        treated at Princess Margaret Cancer Centre.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years.

          2. Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV):

             (I) Histologically confirmed Triple Negative Breast Cancer by Institutional and
             American Society of Clinical Oncology (ASCO)/Cancer of American Pathologists (CAP)
             guidelines, either:

               -  Stage IV (metastatic) disease that has not been treated with systemic therapy in
                  the metastatic setting or

               -  Stage I to III (non-metastatic) with residual mass by clinical exam and/or breast
                  imaging following anthracycline + taxane-containing neoadjuvant chemotherapy

             OR

             (II) Histologically-confirmed Stage IV colorectal cancer treated with â‰¤ 1 line of
             systemic therapy in the metastatic setting, either:

               -  Undergoing surgical resection of liver metastases or

               -  With metastatic lesions amenable to biopsy

             OR

             (III) Histologically-confirmed advanced High Grade Serous Ovarian Cancer, either:

               -  Recurrent disease with a life expectancy of at least 12 months or

               -  Stage III or IV with residual disease following neoadjuvant chemotherapy, or at
                  risk of high recurrence

             OR

             (IV) Histologically confirmed solid tumor not meeting criteria for (I), (II) or (III)
             above, for which evaluation of investigational therapies is of particular interest or
             where clinical need exists, at the discretion of the PI

          3. Disease amenable to biopsy or surgery for tissue procurement

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          5. Willingness and ability of patient to provide signed voluntary informed consent.

        Exclusion Criteria:

          1. Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to
             limit participation in clinical trials.

          2. Known brain metastasis

          3. Any condition that could interfere with a patient's ability to provide informed
             consent such as dementia or severe cognitive impairment.

          4. Any contraindication to undergoing a biopsy procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cescon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Cescon, MD</last_name>
    <phone>416-946-2245</phone>
    <email>Dave.Cescon@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Ho</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>3486</phone_ext>
      <email>catherine.ho@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>David Cescon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>personalized patient-derived xenografts (pPDX)</keyword>
  <keyword>molecular profiling</keyword>
  <keyword>epigenetic analysis</keyword>
  <keyword>drug sensitivity testing</keyword>
  <keyword>triple negative</keyword>
  <keyword>metastatic</keyword>
  <keyword>serous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

